Primary objective: to evaluate the efficacy and safety of De-escalation to lower dose
Ticagrelor (60 mg BID) plus Aspirin (75 mg OD) versus continuation of standard dose
Ticagrelor (90 mg BID) plus Aspirin (75 mg OD), 1 month after primary PCI for STEMI, in
diabetic patients.
Secondary objectives:
To compare tolerability and discontinuation of Ticagrelor in both doses. To compare the 1ry
safety & efficacy endpoints in subgroups with different thrombotic/ischemic risk